Haleon (NYSE:HLN) Shares Break Below Two Hundred Day Moving Average - Should You Sell?

Key Points

• Haleon shares fell below their 200-day moving average of $9.78, reaching $8.38 before last trading at $8.5550 on heavy volume of about 56.8 million shares.
• Analyst sentiment remains mixed but averages to a “Moderate Buy”; ratings include two Strong Buys, three Buys, three Holds and two Sells. The consensus price target is $4.90.
• Institutional investors have been active, with several funds increasing or initiating positions; institutions and hedge funds collectively own 6.67% of Haleon.

Shares of Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $9.78 and traded as low as $8.38. Haleon shares last traded at $8.5550, with a volume of 56,761,965 shares traded.

Analyst Ratings Changes

A number of research firms have commented on HLN. Royal Bank Of Canada restated a "sector perform" rating on shares of Haleon in a research note on Tuesday, August 11th. Morgan Stanley reissued an "overweight" rating on shares of Haleon in a report on Thursday, August 6th. Weiss Ratings restated a "hold (c)" rating on shares of Haleon in a research report on Friday, September 25th. Berenberg Bank reaffirmed a "buy" rating on shares of Haleon in a research note on Wednesday, August 5th. Finally, Wall Street Zen cut shares of Haleon from a "buy" rating to a "hold" rating in a research note on Saturday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $4.90.

Haleon Stock Performance

The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The stock's 50 day moving average price is $9.56 and its 200 day moving average price is $9.78. The company has a market cap of $37.68 billion, a price-to-earnings ratio of 21.94, a P/E/G ratio of 2.26 and a beta of 0.14.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio grew its stake in Haleon by 136.4% during the 1st quarter. Public Employees Retirement System of Ohio now owns 222,708 shares of the company's stock valued at $2,229,000 after purchasing an additional 128,493 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Haleon by 17.0% during the 1st quarter. Bank of America Corp DE now owns 10,934,228 shares of the company's stock valued at $109,452,000 after buying an additional 1,586,230 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Haleon during the second quarter worth approximately $1,186,000. Engineers Gate Manager LP bought a new stake in shares of Haleon in the second quarter worth $1,869,000. Finally, Goodman Financial Corp bought a new stake in shares of Haleon in the first quarter worth $11,488,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Company Profile

Haleon plc NYSE: HLN is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon's well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company's products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.